Regulus Therapeutics Inc (RGLS) — Capital Reinvestment Ratio
Latest as of December 2020:
0.07x
Regulus Therapeutics Inc (RGLS) has a Capital Reinvestment Ratio of 0.07x as of December 2020, meaning it reinvests 0% of its operating cash flow ($3.19 Million) in capital expenditures ($237.00K). See RGLS cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.07x
Capex / Operating Cash Flow
Operating Cash Flow
$3.19 Million
USD
Capital Expenditures
$237.00K
USD
Data as of
Dec 2020
Most recent filing
Regulus Therapeutics Inc Capital Reinvestment Ratio (2010–2010)
This chart tracks Regulus Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Regulus Therapeutics Inc (2010–2010)
Year-by-year Capital Reinvestment Ratio for Regulus Therapeutics Inc from 2010 to 2010. For live market cap and broader valuation context, see RGLS market cap overview.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2010 | 0.20x | $12.31 Million | $2.42 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow